<p>ARS Pharmaceuticals（納斯達克：SPRY - 獲取免費報告）於週四公佈了季度財報。該公司報告本季度每股收益為 0.52 美元，超出市場共識預期的（0.09 美元）0.61 美元，Zacks 報道。</p>
<p>獲取 <strong>ARS Pharmaceuticals</strong> 的提醒：</p>
<h2>ARS Pharmaceuticals 價格表現</h2>
<p>週四，納斯達克 SPRY 上漲 2.82 美元，達到 14.47 美元。該公司股票交易量為 4,254,858 股，而其平均交易量為 1,017,073 股。該股票市值為 14.1 億美元，市盈率為-29.07，貝塔係數為 1.03。ARS Pharmaceuticals 的 12 個月低點為 7.55 美元，12 個月高點為 18.51 美元。該股票的 50 日簡單移動平均為 11.98 美元，200 日簡單移動平均為 13.03 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>SPRY 最近受到多份分析師報告的關注。威廉·布萊爾在 3 月 3 日的報告中重申了對 ARS Pharmaceuticals 股票的 “跑贏大盤” 評級。奧本海默在 2 月 10 日的報告中開始覆蓋 ARS Pharmaceuticals 股票。他們對該股票設定了 “跑贏大盤” 評級和 40.00 美元的目標價。Leerink Partners 在 1 月 13 日的報告中將 ARS Pharmaceuticals 的目標價從 26.00 美元上調至 27.00 美元，並給予該公司 “跑贏大盤” 評級。斯科舍銀行在 3 月 7 日的報告中開始覆蓋 ARS Pharmaceuticals 股票。他們對該股票發佈了 “行業跑贏大盤” 評級和 30.00 美元的目標價。最後，雷蒙德·詹姆斯在 1 月 14 日的研究報告中將 ARS Pharmaceuticals 的目標價從 26.00 美元上調至 28.00 美元，並給予該股票 “強烈買入” 評級。五位股票研究分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，ARS Pharmaceuticals 目前的共識評級為 “買入”，共識目標價為 31.00 美元。</p>
<p><strong>閲讀我們關於 ARS Pharmaceuticals 的最新研究報告</strong></p>
<h2>ARS Pharmaceuticals 的內部交易</h2>
<p>在相關消息中，董事勞拉·肖弗於 3 月 6 日週四出售了 49,600 股該股票。股份以平均價格 11.21 美元出售，總交易額為 556,016.00 美元。交易後，該董事現在持有 210,346 股公司股票，價值約為 2,357,978.66 美元。此交易代表其持股減少了 19.08%。該交易已在提交給證券交易委員會的文件中披露，文件可通過此鏈接訪問。在過去的九十天內，內部人士出售了價值 1,726,516 美元的 149,600 股公司股票。目前，內部人士持有該股票的 40.10%。</p>
<h2>關於 ARS Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>ARS Pharmaceuticals, Inc.是一家生物製藥公司，開發嚴重過敏反應的治療方案。該公司正在開發 neffy，一種無針和低劑量的鼻用腎上腺素噴霧劑，用於急救治療 I 型過敏反應，包括過敏性休克。它為醫療專業人員、患者和護理人員提供服務。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 ARS Pharmaceuticals 更好</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>亞馬遜股票的所有信號都表明買入——是時候加倉了嗎？</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>五個理由説明 Five Below 的股價今年將上漲</li>
<li>三隻沃倫·巴菲特在波動時期必須購買的股票</li>
<li>博通：為什麼這隻芯片股票仍然是長期人工智能投資的首選</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 ARS Pharmaceuticals 嗎？</h2>
<p>在你考慮 ARS Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 ARS Pharmaceuticals 並不在名單上。</p>
<p>雖然 ARS Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

SPRY

<p>ARS Pharmaceuticals（納斯達克代碼：SPRY）報告每股收益為 0.52 美元，超出預期 0.61 美元。股價上漲 2.82 美元，達到 14.47 美元，市值為 14.1 億美元。分析師維持 “買入” 的共識評級，目標價為 31.00 美元。最近的內部交易包括董事 Laura Shawver 出售 49,600 股。該公司專注於開發嚴重過敏反應的治療方法，包括用於過敏性休克的無針腎上腺素鼻噴霧劑</p>

<p>ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.61, Zacks reports.</p>
<div class="lb-trans"><p>ARS Pharmaceuticals（納斯達克：SPRY - 獲取免費報告）於週四公佈了季度財報。該公司報告本季度每股收益為 0.52 美元，超出市場共識預期的（0.09 美元）0.61 美元，Zacks 報道。</p>
</div><p>Get <strong>ARS Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ARS Pharmaceuticals</strong> 的提醒：</p>
</div><h2>ARS Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>ARS Pharmaceuticals 價格表現</h2>
</div><p>NASDAQ SPRY traded up $2.82 on Thursday, reaching $14.47. 4,254,858 shares of the company's stock traded hands, compared to its average volume of 1,017,073. The stock has a market cap of $1.41 billion, a PE ratio of -29.07 and a beta of 1.03. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51. The stock has a 50-day simple moving average of $11.98 and a 200 day simple moving average of $13.03.</p>
<div class="lb-trans"><p>週四，納斯達克 SPRY 上漲 2.82 美元，達到 14.47 美元。該公司股票交易量為 4,254,858 股，而其平均交易量為 1,017,073 股。該股票市值為 14.1 億美元，市盈率為-29.07，貝塔係數為 1.03。ARS Pharmaceuticals 的 12 個月低點為 7.55 美元，12 個月高點為 18.51 美元。該股票的 50 日簡單移動平均為 11.98 美元，200 日簡單移動平均為 13.03 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>SPRY has been the subject of a number of recent analyst reports. William Blair reaffirmed an &#34;outperform&#34; rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an &#34;outperform&#34; rating and a $40.00 target price on the stock. Leerink Partners raised their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, January 13th. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a &#34;sector outperform&#34; rating and a $30.00 price target on the stock. Finally, Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a &#34;strong-buy&#34; rating in a research report on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $31.00.</p>
<div class="lb-trans"><p>SPRY 最近受到多份分析師報告的關注。威廉·布萊爾在 3 月 3 日的報告中重申了對 ARS Pharmaceuticals 股票的 “跑贏大盤” 評級。奧本海默在 2 月 10 日的報告中開始覆蓋 ARS Pharmaceuticals 股票。他們對該股票設定了 “跑贏大盤” 評級和 40.00 美元的目標價。Leerink Partners 在 1 月 13 日的報告中將 ARS Pharmaceuticals 的目標價從 26.00 美元上調至 27.00 美元，並給予該公司 “跑贏大盤” 評級。斯科舍銀行在 3 月 7 日的報告中開始覆蓋 ARS Pharmaceuticals 股票。他們對該股票發佈了 “行業跑贏大盤” 評級和 30.00 美元的目標價。最後，雷蒙德·詹姆斯在 1 月 14 日的研究報告中將 ARS Pharmaceuticals 的目標價從 26.00 美元上調至 28.00 美元，並給予該股票 “強烈買入” 評級。五位股票研究分析師對該股票給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，ARS Pharmaceuticals 目前的共識評級為 “買入”，共識目標價為 31.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on ARS Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 ARS Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Insider Transactions at ARS Pharmaceuticals</h2>
<div class="lb-trans"><h2>ARS Pharmaceuticals 的內部交易</h2>
</div><p>In related news, Director Laura Shawver sold 49,600 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the transaction, the director now owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 149,600 shares of company stock worth $1,726,516. 40.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事勞拉·肖弗於 3 月 6 日週四出售了 49,600 股該股票。股份以平均價格 11.21 美元出售，總交易額為 556,016.00 美元。交易後，該董事現在持有 210,346 股公司股票，價值約為 2,357,978.66 美元。此交易代表其持股減少了 19.08%。該交易已在提交給證券交易委員會的文件中披露，文件可通過此鏈接訪問。在過去的九十天內，內部人士出售了價值 1,726,516 美元的 149,600 股公司股票。目前，內部人士持有該股票的 40.10%。</p>
</div><h2>About ARS Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 ARS Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.</p>
<div class="lb-trans"><p>ARS Pharmaceuticals, Inc.是一家生物製藥公司，開發嚴重過敏反應的治療方案。該公司正在開發 neffy，一種無針和低劑量的鼻用腎上腺素噴霧劑，用於急救治療 I 型過敏反應，包括過敏性休克。它為醫療專業人員、患者和護理人員提供服務。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than ARS Pharmaceuticals</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Everything About Amazon Stock Signals a Buy—Time to Load Up?</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>5 Reasons Five Below’s Stock Price Is Heading Higher This Year</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 ARS Pharmaceuticals 更好</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>亞馬遜股票的所有信號都表明買入——是時候加倉了嗎？</li>
<li>這些液化天然氣股票準備迎來反彈嗎？</li>
<li>五個理由説明 Five Below 的股價今年將上漲</li>
<li>三隻沃倫·巴菲特在波動時期必須購買的股票</li>
<li>博通：為什麼這隻芯片股票仍然是長期人工智能投資的首選</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SPRY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ARS Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ARS Pharmaceuticals 嗎？</h2>
</div><p>Before you consider ARS Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ARS Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 ARS Pharmaceuticals 並不在名單上。</p>
</div><p>While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ARS Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

ARS Pharmaceuticals（納斯達克股票代碼：SPRY）公佈了收益結果，每股收益超出預期 0.61 美元